Lysiane Marthey

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Julien Taı̈eb · 7 shared papers, 2015–2025 · strength 0.49
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
   • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
2. Jean‐Baptiste Bachet · 6 shared papers, 2015–2025 · strength 0.44
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
   • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
3. Romain Coriat · 5 shared papers, 2015–2025 · strength 0.38
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
   • Paper Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Adva… DOI 10.1245/s10434-015-4783-x↗
4. Nicolas Williet · 3 shared papers, 2018–2025 · strength 0.32
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
   • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
5. David Tougeron · 3 shared papers, 2015–2025 · strength 0.30
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
   • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
6. Laëtitia Dahan · 3 shared papers, 2015–2025 · strength 0.26
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
   • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
7. Pascal R. Hammel · 3 shared papers, 2015–2025 · strength 0.26
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
   • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
8. Raëf Abdallah · 2 shared papers, 2021–2025 · strength 0.26
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
9. Isabelle Trouilloud · 3 shared papers, 2015–2025 · strength 0.24
   • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
   • Paper Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Adva… DOI 10.1245/s10434-015-4783-x↗
   • Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
10. António Sá Cunha · 4 shared papers, 2015–2021 · strength 0.24
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
    • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
    • Paper Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Adva… DOI 10.1245/s10434-015-4783-x↗
11. Alix Portal · 2 shared papers, 2015–2025 · strength 0.20
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
    • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
12. Franck Bonnetain · 2 shared papers, 2015–2025 · strength 0.20
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
    • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
13. Simon Pernot · 2 shared papers, 2015–2025 · strength 0.20
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
    • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
14. Christelle de la Fouchardière · 3 shared papers, 2015–2021 · strength 0.18
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
    • Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
    • Paper Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
15. Anne‐Laure Pointet · 1 shared paper, 2025 · strength 0.16
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
16. Jean–Marc Phelip · 1 shared paper, 2025 · strength 0.16
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
17. Camille Evrard · 1 shared paper, 2025 · strength 0.16
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
18. Émilie Soularue · 1 shared paper, 2025 · strength 0.16
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
19. Dominique Béchade · 1 shared paper, 2025 · strength 0.16
    • Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
20. Éric François · 2 shared papers, 2015–2021 · strength 0.14
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
    • Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
21. Thierry Conroy · 2 shared papers, 2016–2018 · strength 0.11
    • Paper Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNI… DOI 10.1016/j.dld.2018.08.008↗
    • Paper FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. DOI 10.1016/s1470-2045(16)00172-8↗
22. Léo Mas · 1 shared paper, 2021 · strength 0.10
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
23. Édouard Auclin · 1 shared paper, 2021 · strength 0.10
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
24. Angélique Vienot · 1 shared paper, 2021 · strength 0.10
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
25. Matthieu Sarabi · 1 shared paper, 2021 · strength 0.10
    • Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.